Literature DB >> 24887059

Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis.

Walter Reinisch1, Andrew R Reinink2, Peter D R Higgins2.   

Abstract

It is a challenge to accurately identify patients with early stage ulcerative colitis (UC) who are at highest risk for a poor outcome and therefore might require salvage therapy. Several epidemiologic and clinical studies have analyzed factors associated with poor prognosis and increased risk for colectomy. We review prognostic factors for adults with newly diagnosed UC and discuss which patients might benefit from rapid and progressive therapy. Patients with poor prognoses tend to be young nonsmokers with high levels of inflammatory biomarkers, low levels of hemoglobin, and extensive disease, based on colonoscopy. We examine these risk factors in 2 hypothetical patients who have been newly diagnosed with UC.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IBD; Prognosis; TNF Inhibitor; Treatment; Tumor Necrosis Factor

Mesh:

Substances:

Year:  2014        PMID: 24887059     DOI: 10.1016/j.cgh.2014.03.037

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

1.  Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study.

Authors:  Yoon Suk Jung; Minkyung Han; Won Ho Kim; Sohee Park; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2017-06-07       Impact factor: 3.199

2.  Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center.

Authors:  Sami Evirgen; Raim İliaz; Filiz Akyüz; Bilger Çavuş; Suut Göktürk; Aslı Örmeci; Özlem Mutluay Soyer; Bülent Baran; Binnur Pınarbaşı; Çetin Karaca; Kadir Demir; Fatih Beşışık; Sabahattin Kaymakoğlu
Journal:  Turk J Gastroenterol       Date:  2022-06       Impact factor: 1.555

3.  Factors Predictive of Proximal Disease Extension and Clinical Course of Patients Initially Diagnosed with Ulcerative Proctitis in an IBD Referral Center.

Authors:  Sandro da Costa Ferreira; Lilian Rose Otoboni Aprile; Rogério Serafim Parra; Marley Ribeiro Feitosa; Gleici de Castro da Silva Perdoná; Omar Féres; José Joaquim Ribeiro da Rocha; Luiz Ernesto de Almeida Troncon
Journal:  Turk J Gastroenterol       Date:  2022-04       Impact factor: 1.555

4.  Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.

Authors:  Stephan R Vavricka; Thomas Greuter; Benjamin L Cohen; Walter Reinisch; Flavio Steinwurz; Marc Fellmann; Xiang Guo; Nervin Lawendy; Jerome Paulissen; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2022-05-10       Impact factor: 4.802

5.  Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors.

Authors:  Hiromitsu Ban; Shigeki Bamba; Atsushi Nishida; Osamu Inatomi; Makoto Shioya; Ken-Ichiro Takahashi; Hirotsugu Imaeda; Masaki Murata; Masaya Sasaki; Tomoyuki Tsujikawa; Akira Andoh
Journal:  Exp Ther Med       Date:  2016-05-16       Impact factor: 2.447

6.  Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort.

Authors:  Johan Burisch; Ryan Ungaro; Ida Vind; Michelle V Prosberg; Flemming Bendtsen; Jean-Frederic Colombel; Marianne K Vester-Andersen
Journal:  J Crohns Colitis       Date:  2017-10-01       Impact factor: 9.071

7.  Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis.

Authors:  Catarina Geraldes de Frias Gomes; Alexandra Sofia Ribeiro de Almeida; Catarina Callé Lucas Mendes; Pierre Ellul; Johan Burisch; Tiffany Buhagiar; Abigail Attard; Bobby Lo; Ryan C Ungaro; Bárbara Tonilhas da Silva Morão; Catarina Ferreira Gouveia; Joana Milheiro Delgado de Carvalho E Branco; Jaime Manuel Martins Pereira Rodrigues; Cristina Teixeira; Maria Francisca Faria Dias de Castro; Gonçalo Filipe Domingos Nunes; Mariana Brito; Marília Cristina de Sousa Antunes; Paula Maria Ferreira Brinca Borralho Nunes; Joana Maria Tinoco da Silva Torres
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

8.  Development and validation of a nomogram to predict indolent course in patients with ulcerative colitis: a single-center retrospective study.

Authors:  Na Li; Shukai Zhan; Caiguang Liu; Tong Li; Tong Tu; Baili Chen; Yao He; Minhu Chen; Zhirong Zeng; Xiaojun Zhuang
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-06-30

9.  Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.

Authors:  Séverine Vermeire; Michael Chiorean; Julián Panés; Laurent Peyrin-Biroulet; Jinkun Zhang; Bruce E Sands; Krisztina Lazin; Preston Klassen; Snehal U Naik; Christopher H Cabell; William J Sandborn
Journal:  J Crohns Colitis       Date:  2021-06-22       Impact factor: 9.071

Review 10.  Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis.

Authors:  Karoline Freeman; Sian Taylor-Phillips; Martin Connock; Rachel Court; Alexander Tsertsvadze; Deepson Shyangdan; Peter Auguste; Hema Mistry; Ramesh Arasaradnam; Paul Sutcliffe; Aileen Clarke
Journal:  BMJ Open       Date:  2017-07-02       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.